Skip to main content
. 2011 May 27;108(24):9939–9944. doi: 10.1073/pnas.1105041108

Fig. 1.

Fig. 1.

Pharmacological trials in RT2 mice using endogenous angiogenesis inhibitors. (A) In vitro viability assay of HUVEC cells treated with antiangiogenesis inhibitor reagents. (B) Prevention trial of RT2 mice from 5.5 to 10 wk of age. For all groups n = 6. (C) An intervention trial was conducted starting at 10 wk of age and continuing to 13.5 wk of age. Endostatin peptide (n = 9), tumstatin peptide (n = 8), and the TSP1 protein (n = 8) all significantly inhibited tumor growth compared with the PBS control group (n = 8). Results are shown as mean ± SEM; *P < 0.05, **P < 0.01.